Precision BioSciences Announces Appointment Of Gene Liau, Ph.D. And Bruce Mccreedy, Ph.D. To Management Team

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Precision BioSciences, the genome editing company, today announced two key additions to the executive team - Gene Liau, Ph.D., as Senior Vice President, Gene Therapy and Bruce McCreedy, Ph.D., as Senior Vice President, Cell Therapy.

"We are excited to welcome Gene and Bruce to the Precision team," said Matthew Kane, Chief Executive Officer of Precision BioSciences. "Their proven leadership and breadth of experience will undoubtedly prove critical to our gene and cell therapy product development programs.

Suggested Articles

VBI's Sci-B-Vac protected twice as many people than GSK's Engerix-B did after the second dose.

The notice comes weeks after Amgen revealed it was retreating from its East Coast neuroscience operations.

Durect's treatment lowered scores that reflect the likelihood a person with alcoholic hepatitis will die within a certain period of time.